-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $145

Benzinga·07/07/2026 11:37:06
Listen to the news
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $121 to $145.